Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Octapharma AG Enters into Agreement with Pfizer

Published: Monday, December 16, 2013
Last Updated: Monday, December 16, 2013
Bookmark and Share
Agreement for the future commercialization and marketing in the U.S. of an investigational intravenous therapy for the urgent reversal of an oral anticoagulant.

Octapharma AG has announced that it has entered into an agreement with Pfizer Inc. for the future marketing and commercialization of human prothrombin complex concentrate (PCC), an investigational agent currently under FDA review for the urgent reversal of Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients who require urgent surgery or invasive procedures.

Under the terms of the agreement, Octapharma AG has exclusive rights to commercialize this product globally, with the exception of the U.S. where Pfizer will exclusively be responsible for marketing and commercialization.

“This collaboration will add value to the overall potential of the compound,” said Octapharma AG Board Member Flemming Nielsen. “Subject to FDA approval of our BLA, the relationship enables the two companies to effectively build on each other’s core capabilities to help meet a need in emergency medicine.”

The BLA for the product was submitted by Octapharma AG in April 2013 and is currently under FDA review. Octapharma AG’s PCC is approved for use in 75 countries outside the U.S. under the brand name Octaplex® and was first approved for use in Germany in 2003 (it is branded as Ocplex® in Sweden and Pronativ® in Australia).

“If the FDA approves this submission, we will combine the expertise of Pfizer’s surgical field force and Octapharma AG’s clinical development program to be able to offer this new treatment in the U.S.,” added William Kennally, Pfizer Established Products North America Regional President.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BAC and Octapharma Extend Recombinant Factor IX Collaboration for Clinical and Commercial Scale Production, and Initiate a Further Blood Disorder Programme
BAC BV, today announced that it has entered into a licence agreement with Octapharma (Lachen, Switzerland) to use BAC’s anti-Factor IX CaptureSelect® affinity ligand in the large scale purification of recombinant Factor IX (FIX).
Monday, November 02, 2009
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos